In a strategic move that underscores the growing significance of biosimilars in global healthcare, Indian pharmaceutical giant Lupin has entered into an exclusive partnership with Zentiva, a prominent European generics player, to market and distribute its proposed biosimilar version of certolizumab pegol. This collaboration positions both companies to tap into the lucrative European market for biologic therapies targeting autoimmune conditions.